Results 141 to 150 of about 2,647 (192)

Discovery of three small-molecule inhibitors targeting <i>Ebolavirus</i> genome replication and transcription. [PDF]

J Gen Virol
Easton V, J McPhillie M, Barr J, Edwards T, Foster R, Fishwick C, Harris M.   +6 more
europepmc   +1 more source

Identification of potential VP40 inhibitor of Marburg virus through molecular docking, pharmacokinetic analysis and molecular dynamics simulation. [PDF]

Sci Rep
Das R, Bhattarai A, Tamang B, Thakur N.
europepmc   +1 more source

Risikokontrolle in Forschungsorganisationen am Beispiel der Genforschung [PDF]

, 1996
Gill, Bernhard, Ludborzs, Boris
core   +1 more source

Study of modulation of anti-oxidative cellular response by VP24 proteins of Marburgvirus and Ebolavirus

, 2012
Les virus Ebola (EBOV) et Marburg (MARV) causent des fièvres hémorragiques chez les primates, y compris l’homme. Le taux de létalité peut atteindre 90% et il n’existe ni vaccin ni traitement contre ces virus. En raison de leurs caractéristiques moléculaires communes, EBOV et MARV sont regroupés au sein de la famille des Filoviridae.
openaire   +1 more source

Evaluation of Probenecid Against Filovirus Replication in Vero E6 Cells. [PDF]

Viruses
Alfson K, Carrion R, Tripp RA, Cirimotich C, Martin DE.   +4 more
europepmc   +1 more source

Genetic diversity of alpha and betacoronaviruses in cave and temple-roosting bats in Vientiane Province, Lao PDR. [PDF]

PLoS One
Mombo IM, Bobouaka Bonguili NC, Gasperini N, Chandarak A, Xaiyaphoumi T, Brault P, Rieu O, Paboriboune P, Leroy E, Niama FR, Locatelli S.   +10 more
europepmc   +1 more source

Infektionskrankheiten als Mitbringsel : Reiselust fördert die Verbreitung von Erregern [PDF]

, 2009
Allwinn, Regina
core  

Marburg Virus Disease: Epidemiology, Immune Responses, and Innovations in Vaccination and Treatment for Enhanced Public Health Strategies. [PDF]

Pathogens
Dzinamarira T, Muvunyi CM.
europepmc   +1 more source

Summary of WHO infection prevention and control guideline for Ebola and Marburg disease: a call for evidence based practice.

BMJ
Willet V, Dixit D, Fisher D, Bausch DG, Ogunsola F, Khabsa J, Akl EA, Baller A, Guideline Development Group.   +8 more
europepmc   +1 more source

Valorization of a Natural Compound Library in Exploring Potential Marburg Virus VP35 Cofactor Inhibitors via an In Silico Drug Discovery Strategy. [PDF]

Curr Issues Mol Biol
Messaoui MM, Ouassaf M, Anede N, Rengasamy KRR, Khan SU, Alhatlani BY.   +5 more
europepmc   +1 more source